Frontiers in Oncology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2201491, encodeId=ed302201491a9, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤细胞免疫 经验分享：分享一下投稿经历，历时6个月，主要是Initial Validation阶段太长了，由于之前已经有文章可以满足毕业要求了，便没催过编辑，希望看到的人（尤其是需要文章毕业的小伙伴）都能中。 02 May 2024 Article accepted for publication. 29 Apr 2024 Submitting Author ** posted new comments in the Editor tab.（当天修回） Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.（审稿人1同意直接发表，便没有回复，看来还是需要把所有审稿人的意见都回复一下） 27 Apr 2024 Review of Review Editor 2 finalized. 23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments. 12 Apr 2024 Interactive review forum activated automatically. 07 Apr 2024 Reviewer 2: Minor revision is required. 07 Mar 2024 Review of Reviewer 1 is finalized. 08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None. 25 Nov 2023 Submitting Author ** resubmitted the manuscript. 23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.（要求提交原始数据） 22 Nov 2023 Submitting Author ** submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=吕心小可爱, createdTime=Thu May 02 18:39:14 CST 2024, time=2024-05-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向：肿瘤 经验分享：各位大佬，请问这个拒稿意见是什么意思啊？ Reason: Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183772, encodeId=9d0c2183e72db, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：感谢群里朋友的无私分享，对我第一篇SCI论文发表帮助很大，再次感谢！ 献上我的投稿过程，供以后的朋友参考： 24 Jan 2024 Article accepted for publication. 08 Jan 2024 Review of Review Editor 1 finalized. 07 Jan 2024 Review of Review Editor 2 finalized. 03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript. 29 Dec 2023 Interactive review forum activated. 11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqT3pba9RQEXLdriaBccULibKA31kTZvGCaJiaDmjyatyogUQM1Pt7OuGdpBTFtWq6owhwh1ScHVibbpg/132, createdBy=92a32211016, createdName=今日崛起, createdTime=Wed Jan 24 23:16:31 CST 2024, time=2024-01-24, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;罕见基因变异;案例报道 经验分享：文章见刊了，好开心，之前参考了大家的投稿经验，分享一下我的投稿历程，传递好运！ 2022.12.14号，提交Manuscript，Initial Validation 2022.12.19号，Editorial Assignment 稿件分配编辑 2023.01.23号，Independent Review Report, Reviewer 1返回审稿意见，这个审稿人提的意见很专业，态度中立 2023.03.14号，两个月没动静，给编辑发了一封催稿邮件，得到回应 2023.03.15号，Reviewer 2返回审稿意见，直接同意发表，审稿意见还是需要在编辑界面单独回复的，限期14天内 2023.03.16，Interactive review交互评审 2023.03.24，提交第一轮审稿意见和修改稿 2023.03.28，Review Finalized 2023.04.07，accepted 2023.04.12，Author's Proof，要求两天内提交 2023.04.25，支付版面费，2020 USD，限期一个月 2023.04.28，在线发表。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信 经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0 偏重的研究方向：诊断;肿瘤;临床 经验分享：临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0 偏重的研究方向：肿瘤 经验分享：来还愿了 修回3天后审稿人全部endorse 第4天就直接accept了 从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=)]

2024-05-02 吕心小可爱来自广东省

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤细胞免疫
经验分享：分享一下投稿经历，历时6个月，主要是Initial Validation阶段太长了，由于之前已经有文章可以满足毕业要求了，便没催过编辑，希望看到的人（尤其是需要文章毕业的小伙伴）都能中。
02 May 2024 Article accepted for publication.
29 Apr 2024
Submitting Author ** posted new comments in the Editor tab.（当天修回）
Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.（审稿人1同意直接发表，便没有回复，看来还是需要把所有审稿人的意见都回复一下）
27 Apr 2024 Review of Review Editor 2 finalized.
23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments.
12 Apr 2024 Interactive review forum activated automatically.
07 Apr 2024 Reviewer 2: Minor revision is required.
07 Mar 2024 Review of Reviewer 1 is finalized.
08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None.
25 Nov 2023 Submitting Author ** resubmitted the manuscript.
23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.（要求提交原始数据）
22 Nov 2023 Submitting Author ** submitted manuscript.

5 0

[GetPortalCommentsPageByObjectIdResponse(id=2201491, encodeId=ed302201491a9, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤细胞免疫 经验分享：分享一下投稿经历，历时6个月，主要是Initial Validation阶段太长了，由于之前已经有文章可以满足毕业要求了，便没催过编辑，希望看到的人（尤其是需要文章毕业的小伙伴）都能中。 02 May 2024 Article accepted for publication. 29 Apr 2024 Submitting Author ** posted new comments in the Editor tab.（当天修回） Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.（审稿人1同意直接发表，便没有回复，看来还是需要把所有审稿人的意见都回复一下） 27 Apr 2024 Review of Review Editor 2 finalized. 23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments. 12 Apr 2024 Interactive review forum activated automatically. 07 Apr 2024 Reviewer 2: Minor revision is required. 07 Mar 2024 Review of Reviewer 1 is finalized. 08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None. 25 Nov 2023 Submitting Author ** resubmitted the manuscript. 23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.（要求提交原始数据） 22 Nov 2023 Submitting Author ** submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=吕心小可爱, createdTime=Thu May 02 18:39:14 CST 2024, time=2024-05-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向：肿瘤 经验分享：各位大佬，请问这个拒稿意见是什么意思啊？ Reason: Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183772, encodeId=9d0c2183e72db, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：感谢群里朋友的无私分享，对我第一篇SCI论文发表帮助很大，再次感谢！ 献上我的投稿过程，供以后的朋友参考： 24 Jan 2024 Article accepted for publication. 08 Jan 2024 Review of Review Editor 1 finalized. 07 Jan 2024 Review of Review Editor 2 finalized. 03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript. 29 Dec 2023 Interactive review forum activated. 11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqT3pba9RQEXLdriaBccULibKA31kTZvGCaJiaDmjyatyogUQM1Pt7OuGdpBTFtWq6owhwh1ScHVibbpg/132, createdBy=92a32211016, createdName=今日崛起, createdTime=Wed Jan 24 23:16:31 CST 2024, time=2024-01-24, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;罕见基因变异;案例报道 经验分享：文章见刊了，好开心，之前参考了大家的投稿经验，分享一下我的投稿历程，传递好运！ 2022.12.14号，提交Manuscript，Initial Validation 2022.12.19号，Editorial Assignment 稿件分配编辑 2023.01.23号，Independent Review Report, Reviewer 1返回审稿意见，这个审稿人提的意见很专业，态度中立 2023.03.14号，两个月没动静，给编辑发了一封催稿邮件，得到回应 2023.03.15号，Reviewer 2返回审稿意见，直接同意发表，审稿意见还是需要在编辑界面单独回复的，限期14天内 2023.03.16，Interactive review交互评审 2023.03.24，提交第一轮审稿意见和修改稿 2023.03.28，Review Finalized 2023.04.07，accepted 2023.04.12，Author's Proof，要求两天内提交 2023.04.25，支付版面费，2020 USD，限期一个月 2023.04.28，在线发表。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信 经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0 偏重的研究方向：诊断;肿瘤;临床 经验分享：临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0 偏重的研究方向：肿瘤 经验分享：来还愿了 修回3天后审稿人全部endorse 第4天就直接accept了 从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=)]

2024-03-25 ms1000000764624599 来自贵州省

偏重的研究方向：肿瘤
经验分享：各位大佬，请问这个拒稿意见是什么意思啊？
Reason:
Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication.

17 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2201491, encodeId=ed302201491a9, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤细胞免疫 经验分享：分享一下投稿经历，历时6个月，主要是Initial Validation阶段太长了，由于之前已经有文章可以满足毕业要求了，便没催过编辑，希望看到的人（尤其是需要文章毕业的小伙伴）都能中。 02 May 2024 Article accepted for publication. 29 Apr 2024 Submitting Author ** posted new comments in the Editor tab.（当天修回） Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.（审稿人1同意直接发表，便没有回复，看来还是需要把所有审稿人的意见都回复一下） 27 Apr 2024 Review of Review Editor 2 finalized. 23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments. 12 Apr 2024 Interactive review forum activated automatically. 07 Apr 2024 Reviewer 2: Minor revision is required. 07 Mar 2024 Review of Reviewer 1 is finalized. 08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None. 25 Nov 2023 Submitting Author ** resubmitted the manuscript. 23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.（要求提交原始数据） 22 Nov 2023 Submitting Author ** submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=吕心小可爱, createdTime=Thu May 02 18:39:14 CST 2024, time=2024-05-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向：肿瘤 经验分享：各位大佬，请问这个拒稿意见是什么意思啊？ Reason: Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183772, encodeId=9d0c2183e72db, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：感谢群里朋友的无私分享，对我第一篇SCI论文发表帮助很大，再次感谢！ 献上我的投稿过程，供以后的朋友参考： 24 Jan 2024 Article accepted for publication. 08 Jan 2024 Review of Review Editor 1 finalized. 07 Jan 2024 Review of Review Editor 2 finalized. 03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript. 29 Dec 2023 Interactive review forum activated. 11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqT3pba9RQEXLdriaBccULibKA31kTZvGCaJiaDmjyatyogUQM1Pt7OuGdpBTFtWq6owhwh1ScHVibbpg/132, createdBy=92a32211016, createdName=今日崛起, createdTime=Wed Jan 24 23:16:31 CST 2024, time=2024-01-24, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;罕见基因变异;案例报道 经验分享：文章见刊了，好开心，之前参考了大家的投稿经验，分享一下我的投稿历程，传递好运！ 2022.12.14号，提交Manuscript，Initial Validation 2022.12.19号，Editorial Assignment 稿件分配编辑 2023.01.23号，Independent Review Report, Reviewer 1返回审稿意见，这个审稿人提的意见很专业，态度中立 2023.03.14号，两个月没动静，给编辑发了一封催稿邮件，得到回应 2023.03.15号，Reviewer 2返回审稿意见，直接同意发表，审稿意见还是需要在编辑界面单独回复的，限期14天内 2023.03.16，Interactive review交互评审 2023.03.24，提交第一轮审稿意见和修改稿 2023.03.28，Review Finalized 2023.04.07，accepted 2023.04.12，Author's Proof，要求两天内提交 2023.04.25，支付版面费，2020 USD，限期一个月 2023.04.28，在线发表。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信 经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0 偏重的研究方向：诊断;肿瘤;临床 经验分享：临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0 偏重的研究方向：肿瘤 经验分享：来还愿了 修回3天后审稿人全部endorse 第4天就直接accept了 从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=)]

2023-04-28 ms1000001631708013 来自浙江省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤;生信
经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！
11 Apr 2023 Article accepted for publication.
07 Apr 2023 Review of Review Editor 3 finalized.
01 Apr 2023 Review of Review Editor 4 finalized.
30 Mar 2023 Review of Review Editor 1 finalized.
17 Mar 2023 Interactive review forum activated.
07 Feb 2023 submitted manuscript

108 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2201491, encodeId=ed302201491a9, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤细胞免疫 经验分享：分享一下投稿经历，历时6个月，主要是Initial Validation阶段太长了，由于之前已经有文章可以满足毕业要求了，便没催过编辑，希望看到的人（尤其是需要文章毕业的小伙伴）都能中。 02 May 2024 Article accepted for publication. 29 Apr 2024 Submitting Author ** posted new comments in the Editor tab.（当天修回） Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.（审稿人1同意直接发表，便没有回复，看来还是需要把所有审稿人的意见都回复一下） 27 Apr 2024 Review of Review Editor 2 finalized. 23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments. 12 Apr 2024 Interactive review forum activated automatically. 07 Apr 2024 Reviewer 2: Minor revision is required. 07 Mar 2024 Review of Reviewer 1 is finalized. 08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None. 25 Nov 2023 Submitting Author ** resubmitted the manuscript. 23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.（要求提交原始数据） 22 Nov 2023 Submitting Author ** submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=吕心小可爱, createdTime=Thu May 02 18:39:14 CST 2024, time=2024-05-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向：肿瘤 经验分享：各位大佬，请问这个拒稿意见是什么意思啊？ Reason: Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183772, encodeId=9d0c2183e72db, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：感谢群里朋友的无私分享，对我第一篇SCI论文发表帮助很大，再次感谢！ 献上我的投稿过程，供以后的朋友参考： 24 Jan 2024 Article accepted for publication. 08 Jan 2024 Review of Review Editor 1 finalized. 07 Jan 2024 Review of Review Editor 2 finalized. 03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript. 29 Dec 2023 Interactive review forum activated. 11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqT3pba9RQEXLdriaBccULibKA31kTZvGCaJiaDmjyatyogUQM1Pt7OuGdpBTFtWq6owhwh1ScHVibbpg/132, createdBy=92a32211016, createdName=今日崛起, createdTime=Wed Jan 24 23:16:31 CST 2024, time=2024-01-24, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;罕见基因变异;案例报道 经验分享：文章见刊了，好开心，之前参考了大家的投稿经验，分享一下我的投稿历程，传递好运！ 2022.12.14号，提交Manuscript，Initial Validation 2022.12.19号，Editorial Assignment 稿件分配编辑 2023.01.23号，Independent Review Report, Reviewer 1返回审稿意见，这个审稿人提的意见很专业，态度中立 2023.03.14号，两个月没动静，给编辑发了一封催稿邮件，得到回应 2023.03.15号，Reviewer 2返回审稿意见，直接同意发表，审稿意见还是需要在编辑界面单独回复的，限期14天内 2023.03.16，Interactive review交互评审 2023.03.24，提交第一轮审稿意见和修改稿 2023.03.28，Review Finalized 2023.04.07，accepted 2023.04.12，Author's Proof，要求两天内提交 2023.04.25，支付版面费，2020 USD，限期一个月 2023.04.28，在线发表。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信 经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0 偏重的研究方向：诊断;肿瘤;临床 经验分享：临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0 偏重的研究方向：肿瘤 经验分享：来还愿了 修回3天后审稿人全部endorse 第4天就直接accept了 从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=)]

2024-01-24 今日崛起来自福建省

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：感谢群里朋友的无私分享，对我第一篇SCI论文发表帮助很大，再次感谢！
献上我的投稿过程，供以后的朋友参考：
24 Jan 2024 Article accepted for publication.
08 Jan 2024 Review of Review Editor 1 finalized.
07 Jan 2024 Review of Review Editor 2 finalized.
03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript.
29 Dec 2023 Interactive review forum activated.
11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript.

34 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2201491, encodeId=ed302201491a9, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤细胞免疫 经验分享：分享一下投稿经历，历时6个月，主要是Initial Validation阶段太长了，由于之前已经有文章可以满足毕业要求了，便没催过编辑，希望看到的人（尤其是需要文章毕业的小伙伴）都能中。 02 May 2024 Article accepted for publication. 29 Apr 2024 Submitting Author ** posted new comments in the Editor tab.（当天修回） Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.（审稿人1同意直接发表，便没有回复，看来还是需要把所有审稿人的意见都回复一下） 27 Apr 2024 Review of Review Editor 2 finalized. 23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments. 12 Apr 2024 Interactive review forum activated automatically. 07 Apr 2024 Reviewer 2: Minor revision is required. 07 Mar 2024 Review of Reviewer 1 is finalized. 08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None. 25 Nov 2023 Submitting Author ** resubmitted the manuscript. 23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.（要求提交原始数据） 22 Nov 2023 Submitting Author ** submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=吕心小可爱, createdTime=Thu May 02 18:39:14 CST 2024, time=2024-05-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向：肿瘤 经验分享：各位大佬，请问这个拒稿意见是什么意思啊？ Reason: Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183772, encodeId=9d0c2183e72db, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：感谢群里朋友的无私分享，对我第一篇SCI论文发表帮助很大，再次感谢！ 献上我的投稿过程，供以后的朋友参考： 24 Jan 2024 Article accepted for publication. 08 Jan 2024 Review of Review Editor 1 finalized. 07 Jan 2024 Review of Review Editor 2 finalized. 03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript. 29 Dec 2023 Interactive review forum activated. 11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqT3pba9RQEXLdriaBccULibKA31kTZvGCaJiaDmjyatyogUQM1Pt7OuGdpBTFtWq6owhwh1ScHVibbpg/132, createdBy=92a32211016, createdName=今日崛起, createdTime=Wed Jan 24 23:16:31 CST 2024, time=2024-01-24, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;罕见基因变异;案例报道 经验分享：文章见刊了，好开心，之前参考了大家的投稿经验，分享一下我的投稿历程，传递好运！ 2022.12.14号，提交Manuscript，Initial Validation 2022.12.19号，Editorial Assignment 稿件分配编辑 2023.01.23号，Independent Review Report, Reviewer 1返回审稿意见，这个审稿人提的意见很专业，态度中立 2023.03.14号，两个月没动静，给编辑发了一封催稿邮件，得到回应 2023.03.15号，Reviewer 2返回审稿意见，直接同意发表，审稿意见还是需要在编辑界面单独回复的，限期14天内 2023.03.16，Interactive review交互评审 2023.03.24，提交第一轮审稿意见和修改稿 2023.03.28，Review Finalized 2023.04.07，accepted 2023.04.12，Author's Proof，要求两天内提交 2023.04.25，支付版面费，2020 USD，限期一个月 2023.04.28，在线发表。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信 经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0 偏重的研究方向：诊断;肿瘤;临床 经验分享：临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0 偏重的研究方向：肿瘤 经验分享：来还愿了 修回3天后审稿人全部endorse 第4天就直接accept了 从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=)]

2023-05-05 ms2000000984739514 来自浙江省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤;罕见基因变异;案例报道
经验分享：文章见刊了，好开心，之前参考了大家的投稿经验，分享一下我的投稿历程，传递好运！
2022.12.14号，提交Manuscript，Initial Validation
2022.12.19号，Editorial Assignment 稿件分配编辑
2023.01.23号，Independent Review Report, Reviewer 1返回审稿意见，这个审稿人提的意见很专业，态度中立
2023.03.14号，两个月没动静，给编辑发了一封催稿邮件，得到回应
2023.03.15号，Reviewer 2返回审稿意见，直接同意发表，审稿意见还是需要在编辑界面单独回复的，限期14天内
2023.03.16，Interactive review交互评审
2023.03.24，提交第一轮审稿意见和修改稿
2023.03.28，Review Finalized
2023.04.07，accepted
2023.04.12，Author's Proof，要求两天内提交
2023.04.25，支付版面费，2020 USD，限期一个月
2023.04.28，在线发表。

95 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2201491, encodeId=ed302201491a9, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤细胞免疫 经验分享：分享一下投稿经历，历时6个月，主要是Initial Validation阶段太长了，由于之前已经有文章可以满足毕业要求了，便没催过编辑，希望看到的人（尤其是需要文章毕业的小伙伴）都能中。 02 May 2024 Article accepted for publication. 29 Apr 2024 Submitting Author ** posted new comments in the Editor tab.（当天修回） Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.（审稿人1同意直接发表，便没有回复，看来还是需要把所有审稿人的意见都回复一下） 27 Apr 2024 Review of Review Editor 2 finalized. 23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments. 12 Apr 2024 Interactive review forum activated automatically. 07 Apr 2024 Reviewer 2: Minor revision is required. 07 Mar 2024 Review of Reviewer 1 is finalized. 08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None. 25 Nov 2023 Submitting Author ** resubmitted the manuscript. 23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.（要求提交原始数据） 22 Nov 2023 Submitting Author ** submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=吕心小可爱, createdTime=Thu May 02 18:39:14 CST 2024, time=2024-05-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向：肿瘤 经验分享：各位大佬，请问这个拒稿意见是什么意思啊？ Reason: Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183772, encodeId=9d0c2183e72db, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：感谢群里朋友的无私分享，对我第一篇SCI论文发表帮助很大，再次感谢！ 献上我的投稿过程，供以后的朋友参考： 24 Jan 2024 Article accepted for publication. 08 Jan 2024 Review of Review Editor 1 finalized. 07 Jan 2024 Review of Review Editor 2 finalized. 03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript. 29 Dec 2023 Interactive review forum activated. 11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqT3pba9RQEXLdriaBccULibKA31kTZvGCaJiaDmjyatyogUQM1Pt7OuGdpBTFtWq6owhwh1ScHVibbpg/132, createdBy=92a32211016, createdName=今日崛起, createdTime=Wed Jan 24 23:16:31 CST 2024, time=2024-01-24, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;罕见基因变异;案例报道 经验分享：文章见刊了，好开心，之前参考了大家的投稿经验，分享一下我的投稿历程，传递好运！ 2022.12.14号，提交Manuscript，Initial Validation 2022.12.19号，Editorial Assignment 稿件分配编辑 2023.01.23号，Independent Review Report, Reviewer 1返回审稿意见，这个审稿人提的意见很专业，态度中立 2023.03.14号，两个月没动静，给编辑发了一封催稿邮件，得到回应 2023.03.15号，Reviewer 2返回审稿意见，直接同意发表，审稿意见还是需要在编辑界面单独回复的，限期14天内 2023.03.16，Interactive review交互评审 2023.03.24，提交第一轮审稿意见和修改稿 2023.03.28，Review Finalized 2023.04.07，accepted 2023.04.12，Author's Proof，要求两天内提交 2023.04.25，支付版面费，2020 USD，限期一个月 2023.04.28，在线发表。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信 经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0 偏重的研究方向：诊断;肿瘤;临床 经验分享：临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0 偏重的研究方向：肿瘤 经验分享：来还愿了 修回3天后审稿人全部endorse 第4天就直接accept了 从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=)]

2024-03-21 ms4000000517261689 来自山东省

偏重的研究方向：肿瘤;免疫治疗;生信
经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…

18 0

[GetPortalCommentsPageByObjectIdResponse(id=2201491, encodeId=ed302201491a9, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤细胞免疫 经验分享：分享一下投稿经历，历时6个月，主要是Initial Validation阶段太长了，由于之前已经有文章可以满足毕业要求了，便没催过编辑，希望看到的人（尤其是需要文章毕业的小伙伴）都能中。 02 May 2024 Article accepted for publication. 29 Apr 2024 Submitting Author ** posted new comments in the Editor tab.（当天修回） Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.（审稿人1同意直接发表，便没有回复，看来还是需要把所有审稿人的意见都回复一下） 27 Apr 2024 Review of Review Editor 2 finalized. 23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments. 12 Apr 2024 Interactive review forum activated automatically. 07 Apr 2024 Reviewer 2: Minor revision is required. 07 Mar 2024 Review of Reviewer 1 is finalized. 08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None. 25 Nov 2023 Submitting Author ** resubmitted the manuscript. 23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.（要求提交原始数据） 22 Nov 2023 Submitting Author ** submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=吕心小可爱, createdTime=Thu May 02 18:39:14 CST 2024, time=2024-05-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向：肿瘤 经验分享：各位大佬，请问这个拒稿意见是什么意思啊？ Reason: Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183772, encodeId=9d0c2183e72db, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：感谢群里朋友的无私分享，对我第一篇SCI论文发表帮助很大，再次感谢！ 献上我的投稿过程，供以后的朋友参考： 24 Jan 2024 Article accepted for publication. 08 Jan 2024 Review of Review Editor 1 finalized. 07 Jan 2024 Review of Review Editor 2 finalized. 03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript. 29 Dec 2023 Interactive review forum activated. 11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqT3pba9RQEXLdriaBccULibKA31kTZvGCaJiaDmjyatyogUQM1Pt7OuGdpBTFtWq6owhwh1ScHVibbpg/132, createdBy=92a32211016, createdName=今日崛起, createdTime=Wed Jan 24 23:16:31 CST 2024, time=2024-01-24, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;罕见基因变异;案例报道 经验分享：文章见刊了，好开心，之前参考了大家的投稿经验，分享一下我的投稿历程，传递好运！ 2022.12.14号，提交Manuscript，Initial Validation 2022.12.19号，Editorial Assignment 稿件分配编辑 2023.01.23号，Independent Review Report, Reviewer 1返回审稿意见，这个审稿人提的意见很专业，态度中立 2023.03.14号，两个月没动静，给编辑发了一封催稿邮件，得到回应 2023.03.15号，Reviewer 2返回审稿意见，直接同意发表，审稿意见还是需要在编辑界面单独回复的，限期14天内 2023.03.16，Interactive review交互评审 2023.03.24，提交第一轮审稿意见和修改稿 2023.03.28，Review Finalized 2023.04.07，accepted 2023.04.12，Author's Proof，要求两天内提交 2023.04.25，支付版面费，2020 USD，限期一个月 2023.04.28，在线发表。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信 经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0 偏重的研究方向：诊断;肿瘤;临床 经验分享：临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0 偏重的研究方向：肿瘤 经验分享：来还愿了 修回3天后审稿人全部endorse 第4天就直接accept了 从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=)]

2024-01-31 mastermaus 来自湖北省

审稿速度:1.0
偏重的研究方向：诊断;肿瘤;临床
经验分享：临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新

31 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2201491, encodeId=ed302201491a9, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤细胞免疫 经验分享：分享一下投稿经历，历时6个月，主要是Initial Validation阶段太长了，由于之前已经有文章可以满足毕业要求了，便没催过编辑，希望看到的人（尤其是需要文章毕业的小伙伴）都能中。 02 May 2024 Article accepted for publication. 29 Apr 2024 Submitting Author ** posted new comments in the Editor tab.（当天修回） Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.（审稿人1同意直接发表，便没有回复，看来还是需要把所有审稿人的意见都回复一下） 27 Apr 2024 Review of Review Editor 2 finalized. 23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments. 12 Apr 2024 Interactive review forum activated automatically. 07 Apr 2024 Reviewer 2: Minor revision is required. 07 Mar 2024 Review of Reviewer 1 is finalized. 08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None. 25 Nov 2023 Submitting Author ** resubmitted the manuscript. 23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.（要求提交原始数据） 22 Nov 2023 Submitting Author ** submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=吕心小可爱, createdTime=Thu May 02 18:39:14 CST 2024, time=2024-05-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向：肿瘤 经验分享：各位大佬，请问这个拒稿意见是什么意思啊？ Reason: Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183772, encodeId=9d0c2183e72db, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：感谢群里朋友的无私分享，对我第一篇SCI论文发表帮助很大，再次感谢！ 献上我的投稿过程，供以后的朋友参考： 24 Jan 2024 Article accepted for publication. 08 Jan 2024 Review of Review Editor 1 finalized. 07 Jan 2024 Review of Review Editor 2 finalized. 03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript. 29 Dec 2023 Interactive review forum activated. 11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqT3pba9RQEXLdriaBccULibKA31kTZvGCaJiaDmjyatyogUQM1Pt7OuGdpBTFtWq6owhwh1ScHVibbpg/132, createdBy=92a32211016, createdName=今日崛起, createdTime=Wed Jan 24 23:16:31 CST 2024, time=2024-01-24, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;罕见基因变异;案例报道 经验分享：文章见刊了，好开心，之前参考了大家的投稿经验，分享一下我的投稿历程，传递好运！ 2022.12.14号，提交Manuscript，Initial Validation 2022.12.19号，Editorial Assignment 稿件分配编辑 2023.01.23号，Independent Review Report, Reviewer 1返回审稿意见，这个审稿人提的意见很专业，态度中立 2023.03.14号，两个月没动静，给编辑发了一封催稿邮件，得到回应 2023.03.15号，Reviewer 2返回审稿意见，直接同意发表，审稿意见还是需要在编辑界面单独回复的，限期14天内 2023.03.16，Interactive review交互评审 2023.03.24，提交第一轮审稿意见和修改稿 2023.03.28，Review Finalized 2023.04.07，accepted 2023.04.12，Author's Proof，要求两天内提交 2023.04.25，支付版面费，2020 USD，限期一个月 2023.04.28，在线发表。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信 经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0 偏重的研究方向：诊断;肿瘤;临床 经验分享：临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0 偏重的研究方向：肿瘤 经验分享：来还愿了 修回3天后审稿人全部endorse 第4天就直接accept了 从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=)]

2024-03-11 第一篇一定要中啊来自江苏省

审稿速度:24.0 | 投稿命中率:5.0
偏重的研究方向：肿瘤
经验分享：其实是很难的

23 0

[GetPortalCommentsPageByObjectIdResponse(id=2201491, encodeId=ed302201491a9, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤细胞免疫 经验分享：分享一下投稿经历，历时6个月，主要是Initial Validation阶段太长了，由于之前已经有文章可以满足毕业要求了，便没催过编辑，希望看到的人（尤其是需要文章毕业的小伙伴）都能中。 02 May 2024 Article accepted for publication. 29 Apr 2024 Submitting Author ** posted new comments in the Editor tab.（当天修回） Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.（审稿人1同意直接发表，便没有回复，看来还是需要把所有审稿人的意见都回复一下） 27 Apr 2024 Review of Review Editor 2 finalized. 23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments. 12 Apr 2024 Interactive review forum activated automatically. 07 Apr 2024 Reviewer 2: Minor revision is required. 07 Mar 2024 Review of Reviewer 1 is finalized. 08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None. 25 Nov 2023 Submitting Author ** resubmitted the manuscript. 23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.（要求提交原始数据） 22 Nov 2023 Submitting Author ** submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=吕心小可爱, createdTime=Thu May 02 18:39:14 CST 2024, time=2024-05-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向：肿瘤 经验分享：各位大佬，请问这个拒稿意见是什么意思啊？ Reason: Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183772, encodeId=9d0c2183e72db, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：感谢群里朋友的无私分享，对我第一篇SCI论文发表帮助很大，再次感谢！ 献上我的投稿过程，供以后的朋友参考： 24 Jan 2024 Article accepted for publication. 08 Jan 2024 Review of Review Editor 1 finalized. 07 Jan 2024 Review of Review Editor 2 finalized. 03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript. 29 Dec 2023 Interactive review forum activated. 11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqT3pba9RQEXLdriaBccULibKA31kTZvGCaJiaDmjyatyogUQM1Pt7OuGdpBTFtWq6owhwh1ScHVibbpg/132, createdBy=92a32211016, createdName=今日崛起, createdTime=Wed Jan 24 23:16:31 CST 2024, time=2024-01-24, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;罕见基因变异;案例报道 经验分享：文章见刊了，好开心，之前参考了大家的投稿经验，分享一下我的投稿历程，传递好运！ 2022.12.14号，提交Manuscript，Initial Validation 2022.12.19号，Editorial Assignment 稿件分配编辑 2023.01.23号，Independent Review Report, Reviewer 1返回审稿意见，这个审稿人提的意见很专业，态度中立 2023.03.14号，两个月没动静，给编辑发了一封催稿邮件，得到回应 2023.03.15号，Reviewer 2返回审稿意见，直接同意发表，审稿意见还是需要在编辑界面单独回复的，限期14天内 2023.03.16，Interactive review交互评审 2023.03.24，提交第一轮审稿意见和修改稿 2023.03.28，Review Finalized 2023.04.07，accepted 2023.04.12，Author's Proof，要求两天内提交 2023.04.25，支付版面费，2020 USD，限期一个月 2023.04.28，在线发表。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信 经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0 偏重的研究方向：诊断;肿瘤;临床 经验分享：临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0 偏重的研究方向：肿瘤 经验分享：来还愿了 修回3天后审稿人全部endorse 第4天就直接accept了 从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=)]

2023-10-30 小鹏友来自重庆

审稿速度:3.0 | 投稿命中率:95.0
偏重的研究方向：肿瘤
经验分享：非常水……😌😌😌😌

58 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2201491, encodeId=ed302201491a9, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤细胞免疫 经验分享：分享一下投稿经历，历时6个月，主要是Initial Validation阶段太长了，由于之前已经有文章可以满足毕业要求了，便没催过编辑，希望看到的人（尤其是需要文章毕业的小伙伴）都能中。 02 May 2024 Article accepted for publication. 29 Apr 2024 Submitting Author ** posted new comments in the Editor tab.（当天修回） Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.（审稿人1同意直接发表，便没有回复，看来还是需要把所有审稿人的意见都回复一下） 27 Apr 2024 Review of Review Editor 2 finalized. 23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments. 12 Apr 2024 Interactive review forum activated automatically. 07 Apr 2024 Reviewer 2: Minor revision is required. 07 Mar 2024 Review of Reviewer 1 is finalized. 08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None. 25 Nov 2023 Submitting Author ** resubmitted the manuscript. 23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.（要求提交原始数据） 22 Nov 2023 Submitting Author ** submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=吕心小可爱, createdTime=Thu May 02 18:39:14 CST 2024, time=2024-05-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向：肿瘤 经验分享：各位大佬，请问这个拒稿意见是什么意思啊？ Reason: Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183772, encodeId=9d0c2183e72db, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：感谢群里朋友的无私分享，对我第一篇SCI论文发表帮助很大，再次感谢！ 献上我的投稿过程，供以后的朋友参考： 24 Jan 2024 Article accepted for publication. 08 Jan 2024 Review of Review Editor 1 finalized. 07 Jan 2024 Review of Review Editor 2 finalized. 03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript. 29 Dec 2023 Interactive review forum activated. 11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqT3pba9RQEXLdriaBccULibKA31kTZvGCaJiaDmjyatyogUQM1Pt7OuGdpBTFtWq6owhwh1ScHVibbpg/132, createdBy=92a32211016, createdName=今日崛起, createdTime=Wed Jan 24 23:16:31 CST 2024, time=2024-01-24, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;罕见基因变异;案例报道 经验分享：文章见刊了，好开心，之前参考了大家的投稿经验，分享一下我的投稿历程，传递好运！ 2022.12.14号，提交Manuscript，Initial Validation 2022.12.19号，Editorial Assignment 稿件分配编辑 2023.01.23号，Independent Review Report, Reviewer 1返回审稿意见，这个审稿人提的意见很专业，态度中立 2023.03.14号，两个月没动静，给编辑发了一封催稿邮件，得到回应 2023.03.15号，Reviewer 2返回审稿意见，直接同意发表，审稿意见还是需要在编辑界面单独回复的，限期14天内 2023.03.16，Interactive review交互评审 2023.03.24，提交第一轮审稿意见和修改稿 2023.03.28，Review Finalized 2023.04.07，accepted 2023.04.12，Author's Proof，要求两天内提交 2023.04.25，支付版面费，2020 USD，限期一个月 2023.04.28，在线发表。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信 经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0 偏重的研究方向：诊断;肿瘤;临床 经验分享：临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0 偏重的研究方向：肿瘤 经验分享：来还愿了 修回3天后审稿人全部endorse 第4天就直接accept了 从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=)]

2021-09-17 146e0980m70暂无昵称

审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0
偏重的研究方向：肿瘤
经验分享：来还愿了
修回3天后审稿人全部endorse
第4天就直接accept了
从投稿到接收差不多两个月左右，这个速度简直感激

304 71

展开71条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务